The amount is still far below what the U.S. spent previously on humanitarian and health aid, but resumes the flow of money for key efforts to fight malnutrition and disease.
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of Latin America remains uncertain.
Most of the people testing positive for Ebola in the Democratic Republic of Congo are not on health workers’ radar, suggesting that contact tracing is lagging dangerously behind.
A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.
